$TNXP
Tonix Pharmaceuticals Holding Corp.

2016 Q1 Form 10-Q Financial Statement

#000114420416099576 Filed on May 06, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.340M $3.910M $2.870M
YoY Change 16.38% 21.05% 77.16%
% of Gross Profit
Research & Development $10.67M $9.490M $6.829M
YoY Change 56.25% 64.19% 92.37%
% of Gross Profit
Depreciation & Amortization $57.00K $70.00K $22.00K
YoY Change 159.09% 250.0% 450.0%
% of Gross Profit
Operating Expenses $14.01M $13.40M $9.696M
YoY Change 44.53% 48.89% 87.58%
Operating Profit -$13.40M -$9.696M
YoY Change 48.84% 87.58%
Interest Expense $40.00K $40.00K $20.00K
YoY Change 100.0% 100.0% 100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$13.98M -$13.36M -$9.680M
YoY Change 44.42% 48.61% 87.6%
Income Tax
% Of Pretax Income
Net Earnings -$13.98M -$13.36M -$9.681M
YoY Change 44.41% 48.63% 87.47%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$699.0M -$668.0M -$968.0M
COMMON SHARES
Basic Shares Outstanding 18.87M shares 18.83M shares 16.14M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.50M $43.00M $58.20M
YoY Change -52.75% 12.57% 17.58%
Cash & Equivalents $8.427M $19.18M $58.18M
Short-Term Investments $19.10M $23.80M
Other Short-Term Assets $3.200M $3.300M $1.800M
YoY Change 77.78% 266.67% 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $30.65M $46.36M $60.00M
YoY Change -48.91% 18.76% 19.76%
LONG-TERM ASSETS
Property, Plant & Equipment $383.0K $350.0K $306.0K
YoY Change 25.16% 6.71%
Goodwill
YoY Change
Intangibles $120.0K $120.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 100.0%
Total Long-Term Assets $692.0K $659.0K $500.0K
YoY Change 38.4% 30.24% 400.0%
TOTAL ASSETS
Total Short-Term Assets $30.65M $46.36M $60.00M
Total Long-Term Assets $692.0K $659.0K $500.0K
Total Assets $31.35M $47.02M $60.50M
YoY Change -48.19% 18.91% 20.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.067M $3.049M $2.000M
YoY Change 3.35% 105.04% 42.86%
Accrued Expenses $1.844M $3.601M $1.500M
YoY Change 22.93% 90.03% 150.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.911M $6.650M $3.500M
YoY Change 11.74% 96.63% 52.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.911M $6.650M $3.500M
Total Long-Term Liabilities $100.0K $100.0K $100.0K
Total Liabilities $4.008M $6.756M $3.600M
YoY Change 11.33% 95.83% 56.52%
SHAREHOLDERS EQUITY
Retained Earnings -$116.4M -$102.4M
YoY Change 88.43%
Common Stock $142.7M
YoY Change 57.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.30M $40.26M $56.90M
YoY Change
Total Liabilities & Shareholders Equity $31.30M $47.02M $60.50M
YoY Change -48.26% 18.91% 20.51%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015 Q1
OPERATING ACTIVITIES
Net Income -$13.98M -$13.36M -$9.681M
YoY Change 44.41% 48.63% 87.47%
Depreciation, Depletion And Amortization $57.00K $70.00K $22.00K
YoY Change 159.09% 250.0% 450.0%
Cash From Operating Activities -$15.49M -$11.91M -$9.050M
YoY Change 71.16% 44.89% 122.91%
INVESTING ACTIVITIES
Capital Expenditures $65.00K -$50.00K $0.00
YoY Change -61.54% -100.0%
Acquisitions
YoY Change
Other Investing Activities $4.780M -$1.870M
YoY Change
Cash From Investing Activities $4.720M -$1.920M $0.00
YoY Change 1500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $29.05M
YoY Change -100.0% -28.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 29.05M
YoY Change -100.0% -100.0% -36.03%
NET CHANGE
Cash From Operating Activities -15.49M -11.91M -9.050M
Cash From Investing Activities 4.720M -1.920M 0.000
Cash From Financing Activities 0.000 0.000 29.05M
Net Change In Cash -10.77M -13.83M 20.00M
YoY Change -153.85% 72.23% -51.63%
FREE CASH FLOW
Cash From Operating Activities -$15.49M -$11.91M -$9.050M
Capital Expenditures $65.00K -$50.00K $0.00
Free Cash Flow -$15.56M -$11.86M -$9.050M
YoY Change 71.88% 46.6% 122.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3168000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3343000 USD
CY2016Q1 us-gaap Assets Current
AssetsCurrent
30654000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
46359000 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
133000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
132000 USD
CY2016Q1 us-gaap Assets
Assets
31346000 USD
CY2015Q4 us-gaap Assets
Assets
47018000 USD
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2067000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3049000 USD
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1844000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3601000 USD
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3911000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6650000 USD
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
97000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-178000 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
38000 USD
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116374000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102398000 USD
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
15000 USD
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-3000 USD
CY2015Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9678000 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-18000 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
43000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13933000 USD
CY2015Q1 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2016Q1 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
25000 USD
CY2016Q1 us-gaap Depreciation
Depreciation
57000 USD
CY2015Q1 us-gaap Depreciation
Depreciation
22000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
896000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1348000 USD
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
383000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
350000 USD
CY2016Q1 us-gaap Security Deposit
SecurityDeposit
56000 USD
CY2015Q4 us-gaap Security Deposit
SecurityDeposit
57000 USD
CY2016Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
120000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8427000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19175000 USD
CY2016Q1 us-gaap Mortgage Backed Securities Available For Sale Fair Value Disclosure
MortgageBackedSecuritiesAvailableForSaleFairValueDisclosure
19059000 USD
CY2015Q4 us-gaap Mortgage Backed Securities Available For Sale Fair Value Disclosure
MortgageBackedSecuritiesAvailableForSaleFairValueDisclosure
23841000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
106000 USD
CY2016Q1 us-gaap Liabilities
Liabilities
4008000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
6756000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
953000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-986000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
502000 USD
CY2016Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1645000 USD
CY2015Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-289000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15485000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9053000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4718000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
29054000 USD
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
19000 USD
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
-4000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58181000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10748000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
19997000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38184000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29054000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
113000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
70000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-9000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2000 USD
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4783000 USD
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2016Q1 tnxp Working Capital Amount
WorkingCapitalAmount
26700000 USD
CY2016Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16576000 USD
CY2016Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2483000 USD
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33000 USD
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
22000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4535000 USD
CY2016Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
19059000 USD
CY2016Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23594000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11791 shares
CY2016Q1 us-gaap Other Commitment
OtherCommitment
21600000 USD
CY2016Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1 pure
CY2016Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.19 pure
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
120000 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18891264 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18891264 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18831669 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18831669 shares
CY2015Q4 tnxp Common Stock Shares To Be Issued
CommonStockSharesToBeIssued
17595 shares
CY2016Q1 tnxp Common Stock Shares To Be Issued
CommonStockSharesToBeIssued
0 shares
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
14014000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
9696000 USD
CY2016Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
113000 USD
CY2016Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
896000 USD
CY2016Q1 tnxp Unrealized Gain On Available For Sale And Trading Securities Net Of Tax
UnrealizedGainOnAvailableForSaleAndTradingSecuritiesNetOfTax
25000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
56250 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
42000 shares
CY2016Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
24000 USD
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in accordance with&#160;accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of fixed assets, assumptions used in the fair value of stock-based compensation and other equity instruments, and the percent of completion of research and development contracts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
683000 USD
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
607000 USD
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
181000 USD
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1975000 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
133000 USD
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
48000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.37
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0.0 USD
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1729217 shares
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
504000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
800000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1300000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
CY2016Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2016Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Risks and uncertainties</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company's primary efforts are devoted to conducting research and development for the treatment of disorders of the central nervous system. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company does not have any commercial products available for sale and has not generated revenues and there is no assurance that if the Food and Drug Administration (&#8220;FDA&#8221;) approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be FDA-approved or commercially viable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At March 31, 2016, the Company had working capital of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">26.7</font> million.&#160; Management believes that the Company has sufficient funds to meet its research and development and other funding requirements for at least the next 12 months. The Company expects that cash used in operations for research and development will increase significantly over the next several years.&#160;In the event such funds are not sufficient to complete the development and commercialization of its current product candidates, the Company intends to raise additional funds through equity or debt financing. If the Company is unsuccessful in raising additional financing, it will need to reduce costs and operations in the future (see Note 8).</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001144204-16-099576-index-headers.html Edgar Link pending
0001144204-16-099576-index.html Edgar Link pending
0001144204-16-099576.txt Edgar Link pending
0001144204-16-099576-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnxp-20160331.xml Edgar Link completed
tnxp-20160331.xsd Edgar Link pending
tnxp-20160331_cal.xml Edgar Link unprocessable
tnxp-20160331_def.xml Edgar Link unprocessable
tnxp-20160331_lab.xml Edgar Link unprocessable
tnxp-20160331_pre.xml Edgar Link unprocessable
v437905_10q.htm Edgar Link pending
v437905_ex31-01.htm Edgar Link pending
v437905_ex31-02.htm Edgar Link pending
v437905_ex32-01.htm Edgar Link pending